Allspring Global Investments Holdings LLC Sells 29,357 Shares of Globus Medical, Inc. $GMED

Allspring Global Investments Holdings LLC trimmed its stake in shares of Globus Medical, Inc. (NYSE:GMED) by 6.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 447,174 shares of the medical device company’s stock after selling 29,357 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.33% of Globus Medical worth $39,038,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in GMED. Advisory Services Network LLC bought a new position in shares of Globus Medical in the 3rd quarter valued at $26,000. EverSource Wealth Advisors LLC increased its stake in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the period. Advisors Asset Management Inc. bought a new position in Globus Medical in the 2nd quarter valued at approximately $28,000. First Horizon Corp bought a new position in Globus Medical in the 3rd quarter valued at approximately $31,000. Finally, Parallel Advisors LLC boosted its position in Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares during the period. Institutional investors own 95.16% of the company’s stock.

Analyst Ratings Changes

GMED has been the subject of several analyst reports. Royal Bank Of Canada raised their price target on shares of Globus Medical from $92.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Truist Financial set a $115.00 price objective on shares of Globus Medical in a research note on Wednesday, February 25th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research note on Tuesday, December 30th. Finally, Canaccord Genuity Group lifted their price objective on Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and an average target price of $104.36.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks raised its Q1 2028 EPS forecast to $1.20 (from $1.19) and reiterated a “Strong‑Buy” rating — a direct, recent upgrade to near‑term earnings expectations that can boost investor confidence. MarketBeat GMED
• Positive Sentiment: Multiple small upward revisions across quarters (Q1–Q3 2026, Q1–Q3 2027) and fiscal years (FY2026, FY2027, FY2028) — including FY2026 to $4.42, FY2027 to $4.67 and FY2028 to $5.19 — suggest Zacks is modeling modestly stronger revenue/profit trends over the next several years. This broad-based upgrade pattern is a constructive signal for growth expectations. MarketBeat GMED
• Neutral Sentiment: Valuation and technical backdrop: GMED trades with a market cap ~ $11.9B and a P/E ~22x; the stock sits near its 50‑day moving average (~$88.9) above the 200‑day (~$80.8). These factors moderate how quickly upgrades translate into price moves — investors will watch upcoming results and guidance for confirmation. MarketBeat GMED

Globus Medical Stock Down 0.0%

Shares of NYSE GMED opened at $87.72 on Friday. The firm has a market cap of $11.86 billion, a PE ratio of 22.26, a P/E/G ratio of 2.05 and a beta of 1.09. The company’s fifty day simple moving average is $88.88 and its 200 day simple moving average is $80.81. Globus Medical, Inc. has a 12-month low of $51.79 and a 12-month high of $101.40.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, beating the consensus estimate of $1.06 by $0.22. The firm had revenue of $826.42 million during the quarter, compared to the consensus estimate of $803.29 million. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The business’s revenue was up 25.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.84 earnings per share. On average, equities analysts predict that Globus Medical, Inc. will post 3.44 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Kelly Huller sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Kyle Kline sold 3,594 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total value of $363,353.40. The disclosure for this sale is available in the SEC filing. Insiders have sold 35,594 shares of company stock worth $3,332,253 in the last quarter. Insiders own 18.51% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.